Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Ria

Showing results (111-120 of 137) with videos related to

Pageof 14
Sort By:
Journal of Clinical Medicine|July 21, 2019
High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor MicroenvironmentAntonio Giovanni Solimando, Matteo Claudio Da Vià, Sebastiano Cicco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2011
Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myelomaAnnunziata De Luisi, Arianna Ferrucci, Addolorata M L Coluccia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2010
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trialAntonio Palumbo, Sara Bringhen, Davide Rossi, et al.
Internal and Emergency Medicine|August 17, 2023
Immune disturbance leads to pulmonary embolism in COVID-19 more than classical risk factors: a clinical and histological studySebastiano Cicco, Antonio Vacca, Federica Albanese, et al.
Blood|September 29, 2011
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairmentFortunato Morabito, Massimo Gentile, Carla Mazzone, et al.
Blood|September 3, 2010
Efficacy and safety of once-weekly bortezomib in multiple myeloma patientsSara Bringhen, Alessandra Larocca, Davide Rossi, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 19, 2018
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete ResponseRoberto Mina, Maria Teresa Petrucci, Paolo Corradini, et al.
Critical Reviews in Oncology/Hematology|November 19, 2018
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trialsMattia D'Agostino, Lorenzo De Paoli, Concetta Conticello, et al.
Blood|December 8, 2009
Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 studyAntonio Palumbo, Sara Bringhen, Benedetto Bruno, et al.
The Lancet. Oncology|November 25, 2015
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trialFrancesca Gay, Stefania Oliva, Maria Teresa Petrucci, et al.
Pageof 14

Showing results (111-120 of 137) with videos related to

Sort By:
Pageof 14
Journal of Clinical Medicine|July 21, 2019
High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor MicroenvironmentAntonio Giovanni Solimando, Matteo Claudio Da Vià, Sebastiano Cicco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2011
Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myelomaAnnunziata De Luisi, Arianna Ferrucci, Addolorata M L Coluccia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2010
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trialAntonio Palumbo, Sara Bringhen, Davide Rossi, et al.
Internal and Emergency Medicine|August 17, 2023
Immune disturbance leads to pulmonary embolism in COVID-19 more than classical risk factors: a clinical and histological studySebastiano Cicco, Antonio Vacca, Federica Albanese, et al.
Blood|September 29, 2011
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairmentFortunato Morabito, Massimo Gentile, Carla Mazzone, et al.
Blood|September 3, 2010
Efficacy and safety of once-weekly bortezomib in multiple myeloma patientsSara Bringhen, Alessandra Larocca, Davide Rossi, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 19, 2018
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete ResponseRoberto Mina, Maria Teresa Petrucci, Paolo Corradini, et al.
Critical Reviews in Oncology/Hematology|November 19, 2018
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trialsMattia D'Agostino, Lorenzo De Paoli, Concetta Conticello, et al.
Blood|December 8, 2009
Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 studyAntonio Palumbo, Sara Bringhen, Benedetto Bruno, et al.
The Lancet. Oncology|November 25, 2015
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trialFrancesca Gay, Stefania Oliva, Maria Teresa Petrucci, et al.
Pageof 14